Protocol Ledger

NCT05408845 · Phase II · RECRUITING

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gl

Interventional Phase II clinical trial protocol NCT05408845 sponsored by NRG Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-03 Enrollment: 146 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05408845
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)146 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05408845
Protocol FieldVerified Registry Value
NCT IdentifierNCT05408845
Consolidated Lead SponsorNRG Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment146 participants (ESTIMATED)
Registered Start Date2023-03-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI